<DOC>
	<DOC>NCT02782078</DOC>
	<brief_summary>Clindamycin and rifampicin are authorized in osteoarticular infection treatment (IDSA guidelines) but some interaction is observed. The objective of this study is to evaluate and quantify rifampicin interaction on clindamycin</brief_summary>
	<brief_title>Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections</brief_title>
	<detailed_description>It could suggest modification of recommended doses or incitement to antibiotic dosage. Thus, theses antibiotics, if association is allowed, could limit fluoroquinolones prescription and avoid some antibiotic resistance.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<criteria>osteoarticular infection staphylococcus sensibility to erythromycin and rifampicin pregnant minor dementia administration of clindamycin and rifampicin one month before treatment with enzymatic inductor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>osteoarticular infection</keyword>
	<keyword>rifampicin</keyword>
	<keyword>clindamycin</keyword>
	<keyword>enzymatic induction</keyword>
	<keyword>antibiotherapy resistance</keyword>
</DOC>